(RTTNews) - Thursday, Pasithea Therapeutics Corp. (KTTA) reported positive initial results from its Phase 1 clinical trial of PAS-004, a new macrocyclic MEK inhibitor aimed at treating ...
Some results have been hidden because they may be inaccessible to you